Checkmate Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2015)
Status: Acquired by Regeneron (2022)

Organization Overview

First Clinical Trial
2016
NCT02680184
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Checkmate Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Squamous Cell (Phase 2)

Colorectal Neoplasms (Phase 1)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 7